

Applicant : Svetomir N. Markovic
Serial No. : 09/187,385
Filed : November 6, 1998
Page : 2 of 6

Attorney's Docket No.: 07039-119001

No claim amendments are proposed. The following Listing of Claims is included for convenience in reviewing the response.

Listing of Claims

1-29. (Canceled)

30. (Previously Presented) A method for stimulating the immune system of a human patient having a resectable malignant tumor, said method comprising:

- a) determining the natural killer lymphocyte cytotoxicity of said patient to provide a baseline natural killer lymphocyte cytotoxicity;
- b) administering an immunostimulatory dosage of an α -interferon composition to said patient, wherein said immunostimulatory dosage increases natural killer lymphocyte cytotoxicity at least about 75% above said baseline natural killer lymphocyte cytotoxicity; and
- c) surgically resecting said malignant tumor, wherein said immunostimulatory dosage is administered to said patient for about five days prior to resecting said malignant tumor.

31-35. (Canceled)

36. (Previously Presented) A method for stimulating the immune system of a human patient having a resectable malignant tumor, said method comprising:

- a) determining the natural killer lymphocyte cytotoxicity of said patient to provide a baseline natural killer lymphocyte cytotoxicity;
- b) administering an immunostimulatory dosage of an α -interferon composition to said patient, wherein said immunostimulatory dosage increases natural killer lymphocyte cytotoxicity at least about 75% above said baseline natural killer lymphocyte cytotoxicity; and
- c) surgically resecting said malignant tumor, wherein said malignant tumor is an early-stage solid tumor.

Applicant : Svetomir N. Markovic
Serial No. : 09/187,385
Filed : November 6, 1998
Page : 3 of 6

Attorney's Docket No.: 07039-119001

37. (Previously Presented) A method for stimulating the immune system of a human patient having a resectable malignant tumor, said method comprising:

- a) determining the natural killer lymphocyte cytotoxicity of said patient to provide a baseline natural killer lymphocyte cytotoxicity;
- b) administering an immunostimulatory dosage of an α -interferon composition to said patient, wherein said immunostimulatory dosage increases natural killer lymphocyte cytotoxicity at least about 75% above said baseline natural killer lymphocyte cytotoxicity; and
- c) surgically resecting said malignant tumor, wherein said malignant tumor is a melanoma.

38-56. (Canceled)